Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aadi Bioscience reports robust FYARRO sales and optimistic outlook for 2023

Aadi Bioscience showcased strong sales performance and financial stability in 2022.
The company's strengths lie in successful product launches, collaborations, and trial outcomes.
Challenges include managing expenses and meeting expectations for future data releases.
Excitement for 2023 signals potential growth opportunities and continued success.

Aadi Bioscience reports revenue growth and clinical progress in Q1

Aadi Bioscience demonstrated strong performance with revenue growth, progress in clinical trials, and a solid financial position.
The company's strengths lie in its product pipeline, clinical trial advancements, and financial stability, positioning it well for future growth.
While facing challenges in sales growth, trial timelines, and global expansion, Aadi Bioscience has opportunities to diversify its portfolio and explore new markets.

Aadi Bioscience reports robust Q2 earnings and expands pipeline offerings

Aadi Bioscience's Q2 performance reflects strong revenue growth, promising pipeline developments, and a solid financial position, positioning the company for future success.
While facing challenges in managing expenses and clinical trials, the company has opportunities to leverage its momentum, expand its market reach, and drive innovation.
Investors should take note of Aadi Bioscience's strategic advancements and financial stability, signaling potential for growth and value creation in the biopharmaceutical sector.

Aadi Bioscience reports solid Q3 results, advances cancer treatment innovations

Aadi Bioscience's Q3 performance reflects financial stability, increased expenses, and progress in advancing nab-Sirolimus for mutated cancers.
The company's strengths lie in new leadership, innovative treatment potential, and a tumor-agnostic trial approach, positioning it for future success.
Challenges include addressing analyst inquiries, meeting trial timeline goals, and managing financial resources effectively amidst growth and innovation.
Opportunities abound in potentially transforming cancer treatment, showcasing advancements, and expanding the pipeline with innovative approaches.

Aadi Bioscience reports robust sales growth and advances in cancer trials

Aadi Bioscience's strong financial performance in 2023, driven by robust FYARRO sales and a focus on operational efficiency, sets a solid foundation for future growth and innovation.
While challenges exist in managing R&D expenses and trial timelines, the company's strategic measures and positive outlook position them well to capitalize on opportunities in expanding their therapeutic reach.
With ongoing trials showing promising results and a proactive approach to presenting new data, Aadi Bioscience remains committed to advancing novel treatments and delivering value to patients and investors alike.

Aadi Bioscience reports steady Q1 sales and optimistic trial progress

Aadi Bioscience's Q1 performance reflects steady sales and strong cash position supporting future operations.
The company's focus on advancing clinical trials and strategic program alignment positions it for future growth.
Challenges in sales and collaboration changes present areas for ongoing monitoring and strategic adjustments.

Aadi Bioscience reports robust Q2 sales and advances in nab-Sirolimus trials

Aadi Bioscience's Q2 performance reflects steady growth in FYARRO sales and progress in nab-Sirolimus trials for various tumor types.
Despite challenges in meeting expectations and market dynamics, the company's strong financial position and confidence in its products are notable strengths.
With a cash runway into Q4 2025 and a promising pipeline, Aadi is poised for growth and success in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations LOS ANGELES , Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA. Abstract and poster presentation details are below: Title: "Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database" Session Title: Poster Session B: Urothelial CarcinomaDate/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST Presenting Author: Gopa Iyer, MDKey Findings: In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2 TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer GU cancers with TSC1 and/or TSC2 inactivating alterations were frequently microsatellite stable and of low tumor mutational burden (TMB) The PRECISION 1 study (NCT05103358) is currently enrolling patients with solid tumors harboring TSC1 and/or TSC2 inactivating alterations Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

- New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- LOS ANGELES , Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.  Abstract and poster presentation details are below: Title: "Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database" Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary TractDate/Time: January 19, 2024 – 12:30 – 2:00 pm Abstract: 558Presenting Author: Dustin Deming, MD Abstract Highlights: In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2 TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers Across GI malignancies, genes frequently mutated in tumors with wild-type TSC1 and TSC2 were similar to genetic mutations co-occurring in tumors with alterations in TSC1 and/or TSC2 Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data.

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

DURECT

Kintara Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations.

Why Is Aadi Bioscience (AADI) Stock Down 56% Today?

Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024 Study on track for completion by end 2024; final data readout expected in early 2025 Company to host conference call today at 5:00 pm EST LOS ANGELES , Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.  "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type.

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

The mean of analysts' price targets for Aadi Bioscience, Inc. (AADI) points to a 510% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Aadi Bioscience, Inc. (AADI)? Wall Street Analysts Think 509.98%

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta Itri - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen Joe Catanzaro - Piper Sandler Roger Song - Jefferies Ahu Demir - Ladenburg Thalmann Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call.

Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript

PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected Latest real-world, next generation sequencing (NGS) analysis reinforces large unmet need in TSC1 and TSC2 mutated cancers FYARRO® sales of $6.0 million in the third quarter, an increase of 40% year-over-year Conference call to be held today at 8:30 am EST LOS ANGELES , Nov. 8, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the quarter ended September 30, 2023, and highlighted recent corporate progress. "The third quarter was marked by strong execution by our Aadi Bio team.

Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update

LOS ANGELES , Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London. Dave Lennon, Ph.D.

Aadi Bioscience to Participate in Jefferies London Healthcare Conference

Company to Host Conference Call and Webcast on Wednesday, November 8, 2023 LOS ANGELES , Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

Aadi initiates  Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC) LOS ANGELES , Oct. 19, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea. Abstract and e-poster presentation details are below: Title: "A phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer"Session Title: e-posterDate/Time: November 5-7, 2023Authors: Lauren E.

Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial testing nab-sirolimus for patients with TSC 1/2 mutations on track for interim analysis on 40 patients before the end of 2023 Evaluation of nab-sirolimus in preclinical combination with PI3K and AKT inhibitors indicate enhanced antitumor effects in PIK3CA-mutated breast cancer LOS ANGELES , Oct. 12, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced details of four poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, MA.  Abstracts and poster presentation details are below: Title: "Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database" Poster Number: C019Session Title: Poster Session CDate/Time: Saturday, October 14, 2023, 12:30 pm-4:00 pm EDT Authors: David J.

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

LOS ANGELES , Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that two posters will be presented at the upcoming North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, taking place October 4-6, 2023, in Montreal, Canada.  Details of the poster presentations are below: Title: "Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced or metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas" Date/Time:  Thursday, October 5, 2023, 5:15 pm – 7:00 pm EDT Presentation Location: Poster Gallery Location, Square Dorchester Presenter: Scott Paulson, MD Authors: Michael J.

Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

LOS ANGELES , Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that an equity award has been granted to its new President and Chief Executive Officer, Dave Lennon, Ph.D., on October 2, 2023, the first date of his employment (the "Grant Date"), in accordance with the Aadi Bioscience, Inc. 2023 Inducement Plan (the "Plan").

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of  2023 LOS ANGELES , Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathway alterations, today announced the appointment of Dave Lennon, Ph.D. as President and Chief Executive Officer.

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events: H.C.

Aadi Bioscience to Participate at Upcoming Investor Conferences

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Scott Giacobello - Interim CEO, President, and CFO Loretta Itri - Chief Medical Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Ahu Demir - Ladenburg Thalmann & Company Boris Peaker - Cowen and Company Roger Song - Jefferies LLC Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience, Incorporated Second Quarter 2023 Earnings Call.

Aadi Bioscience, Inc. (AADI) Q2 2023 Earnings Call Transcript

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago.

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates

Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs) Conference call to be held today at 8:30 am EST LOS ANGELES , Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023. "We are seeing continued growth in FYARRO sales and are pleased with the positive feedback we are receiving from the treatment community," said Scott Giacobello, Interim CEO and President and CFO of Aadi.

Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

Company to Host Conference Call and Webcast on Wednesday, August 9, 2023 LOS ANGELES , Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023 at 8:30 am ET (5:30 am PT) to report second quarter 2023 financial results and provide an operational update. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at www.aadibio.com.

Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

FibroGen

Inogen

Silk Road Medical Inc

Theseus Pharmaceuticals

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types. An investment analysis follows in the paragraphs below.

Aadi Bioscience: High Risk/High Reward

LOS ANGELES , May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL. The abstracts associated with the poster presentations are now available on the ASCO meeting website.

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the following investor events: TD Cowen's 4th Annual Oncology Innovation Summit:  Insights for ASCO & EHA - The virtual event, taking place May 30 - 31, 2023, incorporates fireside chats hosted by members of TD Cowen research team that focus on various aspects of health care. Scott Giacobello, Interim CEO and President and CFO of Aadi, will participate in a fireside chat on Tuesday, May 30, 2023, at 11:30 am ET.

Aadi Bioscience to Participate in Upcoming Investor Events

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations and Corporate Communications Neil Desai - Founder and Executive Chairman Scott Giacobello - Interim Chief Executive Officer, President, and Chief Financial Officer Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies LLC Joseph Catanzaro - Piper Sandler Boris Peaker - Cowen and Company Ahu Demir - Ladenburg Thalmann & Company Operator Good day and welcome to the Aadi Bioscience First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

News for Aadi Bioscience Stock (AADI)